Intellia Therapeutics (NASDAQ: NTLA) has been getting a lot of buzz lately among investors who
US equities could climb another 20% by the end of 2026, fueled by what strategists at Evercore ISI
BYD’s electric car and plug-in hybrid output declined for the second straight month in
Across Europe, frustration over soaring executive pay and government austerity has been boiling
Revolut Ltd. has initiated a secondary share sale that places its valuation at $75 billion,
Your name Your email